Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice
Older patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data.
This study aims to evaluate the impact of older age on the incidence of hematological toxicity in patients with mCRPC treated with docetaxel in daily clinical practice.
This study included patients with mCRPC treated with docetaxel between January 2006 and January 2016 at the Netherlands Cancer Institute and Medical Center Slotervaart for whom dosing and hematological toxicity data were available from electronic patient records. We evaluated the impact of age on the incidence of grade 3 and 4 hematological toxicity.
In total, 175 patients treated with docetaxel were included in the analysis, with a median age of 67 years (range 47–86). Baseline hematological laboratory values were not age related. After the first treatment cycle, hematological toxicity occurred significantly more frequently in the oldest age quartile (25%, p = 0.02) than in the younger age quartiles (9%, 11%, and 7%, respectively, for age quartiles 1, 2, and 3).
The risk of hematological toxicity was significantly higher in the oldest age quartile than in younger patients with mCRPC treated with docetaxel in daily clinical practice.
Compliance with Ethical Standards
No sources of funding were used to assist in the conduct of this study or the preparation of this article.
Conflict of interest
JHB and JHMS are part-time employees and shareholders of Modra Pharmaceuticals and hold a patent on oral taxane pharmaceutical formulations. M-RBSC, AHMdVS, JGCvD, H-MO, AMB, and ADRH have no conflicts of interest that are directly relevant to the content of this article.
- 1.European Medicines Agency. TAXOTERE (docetaxel). 2015. https://doi.org/10.2307/825086.
- 2.European Medicines Agency. Summary of Product Characteristics—Opdivo. 2017.Google Scholar
- 5.Food and Drug Administration. Official label—Taxotere, NDA 020449. 2015.Google Scholar
- 7.Bhatt V, Saleem A. Review: Drug-induced neutropenia—pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34:131–7.Google Scholar
- 8.Sweetman SC. Martindale: the complete drug reference. 38th ed. Pharmaceutical Press; 2014.Google Scholar
- 13.Lipschitz DA, Udupa KB, Milton KY, Thompson CO. Effect of age on hematopoiesis in man. Blood. 1984;63:502–9.Google Scholar
- 16.Gerritse FL, Meulenbeld HJ, Roodhart JML, Van Der Velden MT, Blaisse RJB, Smilde TJ, et al. Analysis of docetaxel therapy in elderly (≥ 70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013;49:3176–83. https://doi.org/10.1016/j.ejca.2013.06.008.
- 19.Jones GR, Lim. E-M. The National Kidney Foundation guideline on estimation of the glomerular filtration rate. Clin Biochem Rev. 2003;24:95–8.Google Scholar
- 20.Institute N Cancer; Common terminology criteria for adverse events (CTCAE). Common terminology criteria for adverse events v4.0 (CTCAE). 2009.Google Scholar
- 23.Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, de Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5:119–26. https://doi.org/10.1016/j.jgo.2013.12.001.Tolerability.CrossRefGoogle Scholar
- 24.Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010;28:4562–7. https://doi.org/10.1200/jco.2010.30.7025.
- 26.Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17:243–56. https://doi.org/10.1016/S1470-2045(15)00489-1.CrossRefGoogle Scholar
- 27.Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. https://doi.org/10.1016/j.ejca.2010.10.013.CrossRefGoogle Scholar
- 28.De Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, et al. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail study. JAMA Oncol. 2017;3:68–75. https://doi.org/10.1001/jamaoncol.2016.3000.CrossRefGoogle Scholar